Topical Pancreatic Duct Lidocaine for Prevention of Post-ERCP Pancreatitis

Completed · Not applicable

Conditions studied: Pancreatitis

In brief

The purpose of this study is to determine if lidocaine is effective in reducing the incidence of post-ERCP pancreatitis.

Key facts

Study ID

NCT00953199

Run by

Abraham Mathew MD

People needed

506

Starts

2010-03-01

Expected to finish

2013-05-01

Last updated by the study team

2017-10-03

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients included are >18 years old, referred to Endoscopy Clinic for an ERCP for any well established indication such as: biliary strictures, benign and malignant hepato-pancreato-biliary tumors, chronic pancreatitis, and suspected sphincter of Oddi dysfunction

You may not qualify if…

• Known sensitivity to lidocaine or contrast agent
• History of seizure disorder
• History of cardiac arrhythmia (tachyarrhythmia, bradyarrhythmia, cardiac conduction defects, prolonged QT syndrome)
• History of congestive heart failure
• Active acute pancreatitis before procedure
• Planned biliary stent removal without pancreatogram
• Pregnancy
• Incarcerated individuals
• Less than 18 years of age
• Previous sphincterotomy
• Inability to give informed consent

Where it is running

• Penn State College of Medicine, Penn State Milton S. Hershey Medical Center — Hershey, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.